AI Verdict
NAKAW has stronger fundamentals based on our AI analysis.
NAMSW vs NAKAW Fundamental Comparison
| Metric | NAMSW | NAKAW |
|---|---|---|
| Revenue | $22.5M | $1.8M |
| Net Income | $-203.8M | $-52.2M |
| Net Margin | -905.7% | -2,867.6% |
| ROE | -29.8% | -10.2% |
| ROA | -26.5% | -7.1% |
| Current Ratio | 7.88x | 1.04x |
| Debt/Equity | 0.00x | 0.00x |
| EPS | $-1.72 | $-0.26 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
NAMSW vs NAKAW: Frequently Asked Questions
Is NAMSW or NAKAW a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), NAKAW has stronger fundamentals. NAMSW is rated STRONG SELL (88% confidence) while NAKAW is rated STRONG SELL (90% confidence). This is not investment advice.
How does NAMSW compare to NAKAW fundamentally?
NewAmsterdam Pharma Co N.V. has ROE of -29.8% vs Nakamoto Inc.'s -10.2%. Net margins are -905.7% vs -2,867.6% respectively.
Which stock pays higher dividends, NAMSW or NAKAW?
NAMSW has a dividend yield of N/A or no dividend while NAKAW has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in NAMSW or NAKAW for long term?
For long-term investing, consider that NAMSW has STRONG SELL rating with 88% confidence, while NAKAW has STRONG SELL rating with 90% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about NAMSW vs NAKAW?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For NAMSW vs NAKAW, the AI consensus favors NAKAW based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.